Jamie has served as Ardelyx’s Chief Human Resources Officer since June 2025, bringing more than 25 years of experience in human resources leadership across the life sciences and technology sectors.
Prior to joining Ardelyx, Jamie served as Chief Human Resources Officer at Spero Therapeutics, where he guided the company through leadership transitions, organizational restructuring and commercial scale-up efforts.
Over the course of his career, Jamie has gathered experience across all aspects of human resources, including talent acquisition, learning and development, total rewards, people technology and operations and more. He has also served in several learning, organization development and organization effectiveness roles.
Before his time at Spero, Jamie held the role of Chief Human Resources Officer at uniQure, as well as roles of increasing responsibility at Intarcia Therapeutics, Genzyme Corporation, and Thomson Financial.
James earned a Bachelor of Arts in history from Marietta College and a Master of Theological Studies from Harvard University.
What is James Parker Brady's net worth?
The estimated net worth of James Parker Brady is at least $1.63 million as of February 20th, 2026. Brady owns 262,912 shares of Ardelyx stock worth more than $1,627,425 as of March 6th. This net worth estimate does not reflect any other investments that Brady may own. Learn More about James Parker Brady's net worth.
How do I contact James Parker Brady?
Has James Parker Brady been buying or selling shares of Ardelyx?
In the last ninety days, James Parker Brady has sold $14,876.55 in Ardelyx stock. Most recently, James Parker Brady sold 2,543 shares of the business's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85, for a transaction totalling $14,876.55. Following the completion of the sale, the insider now directly owns 262,912 shares of the company's stock, valued at $1,538,035.20. Learn More on James Parker Brady's trading history.
Who are Ardelyx's active insiders?
Ardelyx's insider roster includes John Bishop (Insider), Robert Blanks (Insider), James Brady (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Susan Hohenleitner (CFO), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Joseph Reilly (Insider), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?
In the last year, Ardelyx insiders bought shares 5 times. They purchased a total of 1,214,710 shares worth more than $5,349,075.66. In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 575,834 shares worth more than $3,146,127.53. The most recent insider tranaction occured on February, 20th when Director David M Mott bought 333,333 shares worth more than $1,946,664.72. Insiders at Ardelyx own 4.8% of the company.
Learn More about insider trades at Ardelyx. Information on this page was last updated on 2/20/2026.
